NDA Accepted for OnceWeekly Injectable Diabetes DrugJody A. Charnow, Editor
Once-a-month long-acting injectable hydrogel could greatly improve the management of both type 2 diabetes and weight loss, drug adherence, and long-term health outcomes. Researchers in France have developed a once-a-month hydrogel-based delivery system for semaglutide, significantly simplifying dia...
Tirzepatide is a once-weekly injectable, subcutaneous glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.6 It is currently approved by the US Food and Drug Administration (FDA) and European Medicines Agency for treatment of type 2 diabetes in ...
Previous evidence suggests that once-weekly insulin dosing regimens are viewed positively by people with type 2 diabetes16; a study of injectable glucagon-like peptide 1 receptor agonists demonstrated that once-weekly treatments for type 2 diabetes may improve treatment adherence and persistence compared...
superiority trial comparing injectable semaglutide 1.0 mg with placebo as an adjunct to standard of care on kidney outcomes for prevention of progression of renal impairment and risk of renal and cardiovascular mortality in people with type 2 diabet...
For further information, please visit www.Wegovy.com.What is Wegovy®?Wegovy ® (semaglutide) injection 2.4 mg is an injectable prescription medicine that may help adults and children aged 12 years and older with obesity, or some adults with excess weight (overweight) who also have weight-...
Aims:To understand patient preferences for once-daily oral versus once-weekly injectable type 2 diabetes mellitus (T2DM) medication administration profiles... K Boye,M Ross,R Mody,... - 《Diabetes Obesity & Metabolism》 被引量: 0发表: 2021年 Review of head‐to‐head comparisons of glucagon‐...
Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a novel class of injectable antidiabetic drugs. Previous studies indicated that GLP-1R... X Guo,...
Insulin degludec is a unique type of injectable insulin currently in development. In this 16-week, randomized phase 2 proof of concept trial , participants aged 18 to 75 years with type 2 diabetes and glycosylated haemoglobin (HbA1C) of 7•0-11•0 per cent were enrolled and ...
The dulaglutide single-dose pen was found to be a safe and effective device for use by patients with T2D who were injection-nave. A positive injection experience is an important factor for patients and providers when initiating injectable therapy. 2015 Diabetes Technology Society. 展开 ...